Distinguishing Non-Small Cell Lung Adenocarcinoma Patients from Squamous Cell Carcinoma Patients and Control Individuals Using Serum Profiling

被引：6
|
作者：
Hocker, James R. [1 ]
Peyton, Marvin D. [2 ]
Lerner, Megan R. [2 ,3 ]
Lightfoot, Stan A. [3 ,4 ]
Hanas, Rushie J. [1 ]
Brackett, Daniel J. [2 ,3 ]
Hanas, Jay S. [1 ,2 ,3 ]
机构：
[1] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Dept Surg, Oklahoma City, OK 73104 USA
[3] Vet Affairs Med Ctr, Oklahoma City, OK 73104 USA
[4] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA
来源：
CANCER INVESTIGATION | 2012年 / 30卷 / 02期
关键词：
Non-small cell lung cancer; Adenocarcinoma; Squamous cell carcinoma; Serum profiling; Early detection; Predictive value analysis; Electrospray mass spectrometry; OVARIAN-CANCER; IDENTIFICATION; SPECTROMETRY; BIOMARKERS; PROTEOMICS; DISCOVERY;
D O I：
10.3109/07357907.2011.633294
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Goals of this study were to analyze the ability of mass spectrometry serum profiling to distinguish non-small cell lung adenocarcinoma from squamous cell carcinoma patients and healthy controls. Sera were obtained from 19 adenocarcinoma patients, 24 squamous cell carcinoma patients, and 21 controls. Identifications of significant mass-to-charge ratio (m/z) peak differences between these groups were performed using t-tests. A "leave one out" cross-validation procedure yielded discriminatory lung adenocarcinoma versus squamous cell carcinoma p and ROC curve values of < .0001 and 0.92, respectively. Test sensitivity and specificity were 84% and 79%, respectively. This approach could aid in lung cancer diagnosis and sub-typing.
引用
收藏
页码：180 / 188
页数：9
相关论文
共 50 条
  • [21] Loss of heterozygosity (LOH) in non-small cell lung cancer: difference between adenocarcinoma and squamous cell carcinoma
    Yoshino, I
    Osoegawa, A
    Yohena, T
    Kameyama, T
    Oki, E
    Oda, S
    Maehara, Y
    RESPIRATORY MEDICINE, 2005, 99 (03) : 308 - 312
  • [22] Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma"
    Shigeta, Naoko
    Yokose, Tomoyuki
    Murakami, Shuji
    Isaka, Tetsuya
    Shinada, Kanako
    Yoshioka, Emi
    Narita, Atsuya
    Katakura, Kengo
    Kondo, Tetsuro
    Kato, Terufumi
    Nagashima, Takuya
    Saito, Haruhiro
    Ito, Hiroyuki
    THORACIC CANCER, 2024, 15 (06) : 458 - 465
  • [23] MULTIPLEXED ANALYSIS OF LUNG CANCER FOR DISTINGUISHING ADENOCARCINOMA FROM SQUAMOUS CELL CARCINOMA
    Kaanumalle, Lakshmi S.
    Kamath, Vidya
    Al-Kofahi, Yousef
    Bove, Kathleen
    Beck, Rod
    Hollman, Denise
    Ginty, Fiona
    Kim, Edward
    Sarachan, Brion D.
    Lazare, Mike
    Lowes, Christina
    Ring, Brian
    Ong, Teng J.
    Li, Qing
    Santamaria-Pang, Alberto
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S453 - S454
  • [24] The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies
    Hsiang-Ling Ho
    Hua-Lin Kao
    Yi-Chen Yeh
    Teh-Ying Chou
    Diagnostic Pathology, 14
  • [25] The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies
    Ho, Hsiang-Ling
    Kao, Hua-Lin
    Yeh, Yi-Chen
    Chou, Teh-Ying
    DIAGNOSTIC PATHOLOGY, 2019, 14 (1)
  • [26] Impact of KRAS mutation on response and outcome of patients with stageIII non-squamous non-small cell lung cancer
    Yagishita, Shigehiro
    Horinouchi, Hidehito
    Sunami, Kuniko S.
    Kanda, Shintaro
    Fujiwara, Yutaka
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Sumi, Minako
    Shiraishi, Kouya
    Kohno, Takashi
    Furuta, Koh
    Tsuta, Koji
    Tamura, Tomohide
    Ohe, Yuichiro
    CANCER SCIENCE, 2015, 106 (10) : 1402 - 1407
  • [27] Management of EGFR mutated non-small cell lung carcinoma patients
    Perquis, M. -P.
    Tissot, C.
    Bouleftour, W.
    Bayle-Bleuez, S.
    Vercherin, P.
    Forest, F.
    Fournel, P.
    REVUE DES MALADIES RESPIRATOIRES, 2022, 39 (09) : 731 - 739
  • [28] Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma
    Tsao, Anne S.
    Liu, Suyu
    Fujimoto, Junya
    Wistuba, Ignacio I.
    Lee, J. Jack
    Marom, Edith M.
    Charnsangavej, Chusilp
    Fossella, Frank V.
    Tran, Hai T.
    Blumenschein, George R.
    Papadimitrakopoulou, Vassiliki
    Kies, Merrill S.
    Hong, Waun K.
    Stewart, David J.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (12) : 2104 - 2111
  • [29] Molecular landscape of non-squamous, non-small cell carcinoma of the lung
    Weiss, Mia C.
    Leukam, Michael J.
    Villaflor, Victoria M.
    TRANSLATIONAL CANCER RESEARCH, 2015, 4 (04) : 423 - 434
  • [30] From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma
    Thomas, A.
    Rajan, A.
    Lopez-Chavez, A.
    Wang, Y.
    Giaccone, G.
    ANNALS OF ONCOLOGY, 2013, 24 (03) : 577 - 585
12345